Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Giuseppe De Cataldis"'
Autor:
Raffaele Costanzo, Gianfranco Filippelli, Giacomo Vessia, Laura Palmeri, R. Cioffi, Pasquale Comella, Antonio Avallone, Luca Franco, Luigi Maiorino, Ettore Greco, Vincenzo E. Chiuri, Giuseppe De Cataldis, S. Mancarella, Carlo Putzu
Publikováno v:
Lung Cancer. 68:94-98
Purpose To estimate the safety, activity, and impact on quality of life of a combination of gemcitabine and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in the context of a randomized two-stage phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd51b78893c5015652f4d00cb0d583e3
https://doi.org/10.1016/j.lungcan.2009.05.008
https://doi.org/10.1016/j.lungcan.2009.05.008
Autor:
Antonio Gambardella, G. Condemi, Antonio Avallone, Carlo Putzu, Giuseppe De Cataldis, Enrico Barbato, Luca Franco, Bruno Massidda, Pasquale Comella
Publikováno v:
Lung Cancer. 56:263-271
Summary Purpose This study was undertaken to select the best schedule of administration for the paclitaxel plus gemcitabine combination in fit elderly patients affected by locally advanced or metastatic non-small cell lung cancer (NSCLC). Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c2778b3a606f644c568407071bc0d09
https://doi.org/10.1016/j.lungcan.2006.12.015
https://doi.org/10.1016/j.lungcan.2006.12.015
Autor:
F. Rivellini, Giuseppe Comella, Luigi Maiorino, Luigi De Lucia, Pasquale Comella, Giuseppe De Cataldis, Antonio Avallone, Rossana Casaretti, M. Biglietto, Liberato Di Lullo
Publikováno v:
Oncology. 60:127-133
Purpose: To define the maximum tolerated dose (MTD) of irinotecan (CPT-11) given on days 1 and 8 with mitomycin C (MMC) given on day 1 in a monthly cycle, and to assess the toxicity and activity of this regimen in patients with previously treated col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fafa14c4538c5185f74ef79b527a3cdd
https://doi.org/10.1159/000055309
https://doi.org/10.1159/000055309
Autor:
Luigi Maiorino, Giuseppe De Cataldis, G.P. Nicolella, Vito Lorusso, A Lamberti, R. Cioffi, Angelo Di Nota, Giuseppe Frasci, S. Mancarella, E. Micillo, Pasquale Comella, Domenico Bilancia, N. Panza, Luigi Manzione, Michele Di Natale, Giuseppe Comella
Publikováno v:
Clinical Lung Cancer. 1:202-207
In a previous phase II randomized study, a cisplatin/gemcitabine/vinorelbine (PGV) regimen produced a 50-week median survival time (MST) in advanced non–small-cell lung cancer (NSCLC) patients. The present trial was planned to randomly compare the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::706ccae4a7957e34b0bbf602fe0ed78e
https://doi.org/10.3816/clc.2000.n.003
https://doi.org/10.3816/clc.2000.n.003
Autor:
Vincenza Tinessa, Michele Della Vittoria Scarpati, Giuseppe De Cataldis, Alfonso Maiorino, Pasquale Comella, Giovanni P. Ianniello, Alessandra Lombardi, Luigi Brancaccio, Pietro Carnicelli, Riccardo Cioffi
Publikováno v:
Cancer. 78:63-69
BACKGROUND Lonidamine (LND) is an indazol-carboxylic acid derivative that selectively inhibits the energy metabolism of neoplastic cells, and increases the permeability of cell membranes. In vitro studies have demonstrated that LND can potentiate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca7a5a56962e65c18546ab24ff41c55
https://doi.org/10.1002/(sici)1097-0142(19960701)78:1<63::aid-cncr11>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19960701)78:1<63::aid-cncr11>3.0.co
Autor:
Pasquale, Comella, Vincenzo E, Chiuri, Giuseppe, De Cataldis, Gianfranco, Filippelli, Luigi, Maiorino, Giacomo, Vessia, Riccardo, Cioffi, Sergio, Mancarella, Carlo, Putzu, Ettore, Greco, Laura, Palmeri, Raffaele, Costanzo, Antonio, Avallone, Luca, Franco
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 68(1)
To estimate the safety, activity, and impact on quality of life of a combination of gemcitabine and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in the context of a randomized two-stage phase II study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7792d5f20862e577d8e213629b18bfc5
https://pubmed.ncbi.nlm.nih.gov/19545929
https://pubmed.ncbi.nlm.nih.gov/19545929
Autor:
Ferdinando De Vita, Giuseppe De Cataldis, Michele Orditura, Giuseppe Catalano, Fortunato Ciardiello, Gennaro Galizia, Paolo Castellano, Teresa Troiani, Eva Lieto, Francesca Ferraraccio
Publikováno v:
World Journal of Surgical Oncology
World Journal of Surgical Oncology, Vol 5, Iss 1, p 42 (2007)
World Journal of Surgical Oncology, Vol 5, Iss 1, p 42 (2007)
Background Hepatoid adenocarcinoma (HAC) is a peculiar type of extrahepatic adenocarcinoma generally characterized by adenocarcinomatous and hepatocellular carcinoma (HCC)-like foci. Stomach is the most frequent site where hepatoid adenocarcinoma occ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882617f33e05cd34a78b5d21d83fc9d1
https://pubmed.ncbi.nlm.nih.gov/17448253
https://pubmed.ncbi.nlm.nih.gov/17448253
Autor:
Pasquale, Comella, Carlo, Putzu, Bruno, Massidda, Giovanni, Condemi, Giuseppe, De Cataldis, Enrico, Barbato, Antonio, Gambardella, Antonio, Avallone, Luca, Franco
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 56(2)
This study was undertaken to select the best schedule of administration for the paclitaxel plus gemcitabine combination in fit elderly patients affected by locally advanced or metastatic non-small cell lung cancer (NSCLC).Ninety-eight patients in sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eee5ba280e3767437fafc35e65a99d12
https://pubmed.ncbi.nlm.nih.gov/17298853
https://pubmed.ncbi.nlm.nih.gov/17298853
Autor:
Luigi De Lucia, D. Natale, Luigi Maiorino, Sergio Palmeri, Giuseppe De Cataldis, Franco Buzzi, S. Mancarella, Pasquale Comella, Silvana Leo, Bruno Massidda, Antonio Farris, Gianfranco Filippelli, Salvatore Tafuto, Mario Roselli, Vito Lorusso
Publikováno v:
Clinical colorectal cancer. 5(3)
Background A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5a1dd59d88774563ac27388c29d5289
https://pubmed.ncbi.nlm.nih.gov/16197624
https://pubmed.ncbi.nlm.nih.gov/16197624
Autor:
Ferdinando De Vita, Michele Orditura, S Infusino, Giuseppe De Cataldis, Giuseppe Catalano, Gennaro Galizia, Ciro Romano, Eva Lieto
Publikováno v:
Scopus-Elsevier
Interleukin(IL)-2 is a T helper (Th) 1 type cytokine that has been shown to play an important role in antitumour immune responses. In this study, the prognostic significance of serum IL-2 levels was investigated in 60 advanced non-small-cell lung can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b167d7f79be25c30f91a689243c1e930
https://pubmed.ncbi.nlm.nih.gov/11129323
https://pubmed.ncbi.nlm.nih.gov/11129323